Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Theradiag Group/Prestizia

Request full access

Developing, manufacturing, and marketing innovative in-vitro diagnostics

Croissy-Beaubourg, FranceFounded 1986Biotech & Life Sciences

About Theradiag Group/Prestizia

Theradiag, established in 1986 by two former executives of Abbott France, is a company specializing in in-vitro diagnostics (IVD) and theranostics. Initially focused on distributing IVD tests for autoimmune diseases, the company has since expanded its operations significantly. A major turning point was its initial public offering on the NYSE Alternext in December 2012, at which time it changed its name from BMD to Theradiag. In December 2023, Theradiag completed a merger-absorption by Biosynex.

The company's business is structured around two main activities: In-Vitro Diagnostics and Theranostics. The IVD segment covers both in-house manufactured products and distributed products in fields such as autoimmunity, allergies, and infectious diseases. The Theranostics division, a key growth driver, focuses on providing personalized medicine solutions for monitoring biotherapies used in treating autoimmune diseases and cancer. This is centered around its flagship LISA TRACKER® range, a comprehensive set of tests for monitoring monoclonal antibodies. Revenue is generated through the sale of these diagnostic kits and reagents, as well as through licensing agreements and the sale of raw materials to partners. For the fiscal year 2022, Theradiag reported revenue of €12.2 million.

Theradiag's product portfolio is designed to aid clinicians in customizing treatments, evaluating their efficacy, and preventing drug resistance. Key products include the CE-marked TRACKER® range, which has expanded into oncology for monitoring treatments like Rituximab and Bevacizumab. The company also develops and markets the i-Tracker® range of tests adapted for its i-Track10 automated system, which has been a significant contributor to sales growth. Furthermore, Theradiag has developed ez-TRACKER®, a point-of-care testing machine for on-site diagnostics. The firm's expertise in diagnostics for autoimmune diseases is supported by its multiplex test range using Luminex® technology. In 2012, Theradiag acquired Prestizia to develop new diagnostic markers using a microRNA platform. However, this subsidiary was closed in 2017 after research programs were deemed not robust enough for commercialization.

Source: Dealroom company data

Theradiag Group/Prestizia in the Croissy-Beaubourg ecosystem

Live from Dealroom

The Theradiag Group/Prestizia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Ventech
  • Auriga Partners
  • Innovation Capital
  • Sofinnova Investments
  • Siparex
  • Eurazeo
  • Truffle Capital
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇷 France92.2%
🇺🇸 United States5.9%
🇮🇱 Israel2%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Theradiag Group/Prestizia on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Theradiag Group/Prestizia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.